All research

Research report · October 30, 2026

FLRY3

Fleury S.A.

B3 listed Healthcare São Paulo, Brazil

Reference price

R$ 20.47

+23.31% over 90 days

Consensus across all agents

Research synthesis

Neutral · 86%
The combined view is clear: this is a good business, but not an especially compelling stock at the current price. Both perspectives agree the company has many attractive qualities — it has stayed profitable for a long time, appears financially disciplined, operates in a durable and necessary area, and has treated shareholders reasonably well through consistent payouts. Those are the traits that usually support a solid long-term investment case. Where the case weakens is valuation. Both analysts independently reach the same conclusion that the shares do not offer enough room for error. In other words, much of the company’s quality already seems reflected in the price. That matters because even strong businesses can produce mediocre returns if bought too expensively. There is only modest disagreement around management alignment and the smoothness of earnings growth, but those are secondary issues here. The main message is not that the business is flawed; it is that the current setup does not provide a favorable balance between quality and price. For most investors, that points to patience rather than action. The final assessment is neutral: worth respecting, worth watching, but not clearly attractive enough to buy aggressively right now.
Strength

Business quality is high — durable operations, strong finances, and a long record of profitability support resilience.

Caution

Margin of safety is weak — buyers today may be paying too much for a quality business already fully valued.

Watch

A more attractive entry price or clearer evidence of steadier earnings growth would strengthen the investment case.

Agent conviction.

Value & Moat agent

Warren Buffett

Neutral · 84%
If I were looking at this the way I’ve always tried to look at businesses, I would begin by saying this appears to be a genuinely good company. It operates in a field that people need regardless of fashion or economic excitement, and it seems to have built a durable position through dependable medical services. That is the sort of business I prefer to study: understandable, necessary, and not easily made obsolete overnight. The company also seems to possess several qualities I admire. It has shown an ability to earn well on the capital entrusted to it, which usually tells you the underlying business is sound rather than merely busy. It has also avoided leaning too heavily on debt, and that matters a great deal. A good business does not need to perform financial acrobatics to look successful. It should be able to stand on its own feet. On the operating side, the picture is encouraging. The business has expanded over time, remained profitable, and appears to have a reasonably steady economic engine. That kind of consistency is valuable because investing gets much easier when you can make a sensible judgment about where a business is likely to be years from now. While the growth in bottom-line results has not been perfectly smooth, the overall pattern still suggests a capable enterprise rather than a fragile one. Management appears respectable, though not flawless from an owner’s perspective. The record of maintaining profitability and returning cash to shareholders suggests seriousness and discipline. However, I always like to see clear evidence that managers think and act like long-term owners. When that alignment is less obvious, I become a bit more reserved. It does not make the business unattractive, but it does affect how enthusiastic I am. Now we come to the part that matters just as much as business quality: price. A wonderful business can still be a poor investment if purchased at too dear a price. In fact, paying too much for even an excellent company can turn a sensible decision into a disappointing one. The information you’ve given says the shares are selling above a reasonable estimate of intrinsic worth, with no real cushion for error. That lack of a margin of safety is important. In investing, you do not need to swing at every pitch. You wait for the ones that are both good businesses and available at a sensible price. So my conclusion would be neutral. I would not dismiss the company, because the business itself appears attractive. But I also would not rush to buy it simply because it is a good company. Buffett-style investing is not about buying quality at any price; it is about buying quality when price and value are working in your favor. Here, the business passes many of the qualitative tests, but the current price seems to remove the protection that prudent investing requires. In plain language: this looks like a fine house in a good neighborhood, but the asking price is too high to promise a satisfactory long-term result. I would keep it on the watchlist, admire the business, and wait patiently for a more favorable opportunity.

Scoring radar

Fundamentals
ROE 100/100
ROIC 100/100
Leverage 100/100
Consistency
Revenue 100/100
Margin 100/100
Net Income 70/100
Management
Ownership 28/100
Earnings 90/100
Payout 100/100
Valuation 0/100

Financial metrics.

Revenue vs net income

BRL thousands · 2014–2025

Revenue Net income

Balance sheet components

BRL thousands · 2014–2025

Fixed assets Other Net debt Working capital

Leverage & efficiency

Debt to equity 0.4x

Moderate leverage - acceptable for healthcare.

Operating margin 15.0%

Consistently positive operating margin with low variability.

Return on equity 2.0x

Return on equity has consistently exceeded the cost of capital, indicating value creation.

Return on invested capital 1.5x

Return on invested capital has consistently exceeded the cost of capital, indicating value creation.

Operating margin

% · 2014–2025

Ownership & distributions.

Voting ownership

Shareholder Voting %
Bradesco Group 24.8%
Family Pardini 19.7%
Free float 55.5%

Payout history

Dividend per share

R$ 0.863

Dec 2025

Dividend per share

R$ 0.931

Dec 2024

Dividend per share

R$ 0.494

Dec 2023

Dividend per share

R$ 0.238

Dec 2022